---
title: "BMRN.US (BMRN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BMRN.US/news.md"
symbol: "BMRN.US"
name: "BMRN.US"
parent: "https://longbridge.com/en/quote/BMRN.US.md"
datetime: "2026-05-20T01:52:22.527Z"
locales:
  - [en](https://longbridge.com/en/quote/BMRN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BMRN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BMRN.US/news.md)
---

# BMRN.US (BMRN.US) — Related News

### [Citigroup is optimistic about the catalysts and growth prospects, covering Ionis, Alnylam, and BioMarin with a buy rating](https://longbridge.com/en/news/286956616.md)
*2026-05-19T19:15:30.000Z*
> Citigroup has initiated coverage on the small and mid-cap biotech sector, giving "Buy" ratings to Ionis, Alnylam, and Bi

### [Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness](https://longbridge.com/en/news/286895616.md)
*2026-05-19T10:29:59.000Z*
> BioMarin Pharmaceutical (BMRN) has seen a decline in its stock price, down 4% in a day and 17% over three months, raisin

### [Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50](https://longbridge.com/en/news/286870032.md)
*2026-05-19T07:14:23.000Z*
> BioMarin’s BMN 401 raised plasma PPi over 52 weeks in children but showed no meaningful rickets or growth improvement. S

### [BioMarin's ENPP1 deficiency phase III clinical trial fails, BMN 401 does not reach clinical benefit endpoint](https://longbridge.com/en/news/286795745.md)
*2026-05-18T15:48:57.000Z*
> BioMarin Pharmaceutical Inc. announced the results of the Phase III ENERGY 3 trial for children aged 1 to 12 with ENPP1 

### [BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | BMRN Stock News](https://longbridge.com/en/news/286776398.md)
*2026-05-18T05:05:30.000Z*
> BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | BMRN Stock News